GlobalRPH - ADHD News

Medical News

< back to feeds
ADHD News
Shire Reports Analysis Examining Emotional Lability In Children With ADHD Taking Vyvanse Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years. ...more	14 Nov 2009
Queen's And Yale Researchers Win Award For Study That Links Health And Education Queen's University researcher Steven Lehrer has won a prestigious international award in recognition of his contributions to health economics. A professor in Queen's School of Policy Studies and Department of Economics, Dr. Lehrer shares the RAND Corporation's Victor R. Fuchs Research Award with Jason Fletcher of Yale University. ...more	13 Nov 2009
Shire Reports Findings From An Analysis Examining Emotional Lability In Children With ADHD Taking Vyvanse(R) (lisdexamfetamine Dimesylate) Capsules Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years. ...more	13 Nov 2009
ADHD: Once-Daily INTUNIV (Guanfacine) Extended Release Tablets Now Available In US Pharmacies Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company,has announced the availability of INTUNIV™ (guanfacine) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17. INTUNIV, a once-daily formulation of guanfacine, is the first and only nonscheduled alpha-2A receptor agonist approved for the treatment of ADHD. ...more	11 Nov 2009
The Importance Of Language Support For Children With Autism Teachers and parents must be vigilant in observing difficulties with language comprehension, reading and spelling in children and young people with autism, Asperger's syndrome and ADHD. "It is important that pupils are offered the support to which they are entitled", says Jakob Ã�sberg in a new thesis at the University of Gothenburg. "Pupils with these neuropsychiatric disorders are often reported as having problems with spoken and written activities. ...more	10 Nov 2009
Objective Measures Of ADHD Symptoms Using The Quotient(TM) ADHD System May Reduce Cost Of ADHD Drug Trials BioBehavioral Diagnostics Company announced that its poster was presented Friday, October 30, 2009 after it was accepted via a rigorous peer-review process and included as a New Research Poster presentation at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in Honolulu, HI, October 27-November 1, 2009. Calvin R. Sumner, M.D. ...more	03 Nov 2009
Shire Reports Tolerability And Clinical Effects Results Of Daytrana(R) (methylphenidate Transdermal System) From Study In Adolescents With ADHD Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD). In addition, data regarding the pharmacokinetic profile of Daytrana in children and adolescents was also presented. ...more	31 Oct 2009
Study Findings On ADHD Treatments Presented At Psychiatric Meeting Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV™ (guanfacine) Extended Release Tablets, Vyvanse® (lisdexamfetamine dimesylate) Capsules CII, and Daytrana® (methylphenidate transdermal system) CII, at a national meeting of psychiatrists being held October 27 - November 1 in Honolulu. ...more	30 Oct 2009
Attention-Deficit/Hyperactivity Problems Associated With Low Folate Levels In Pregnant Women It has long been suggested that healthy folate (the natural form of folic acid) levels in expectant mothers goes hand in hand with healthy nervous system development in their children. A study published in an upcoming issue of The Journal of Child Psychology and Psychiatry finds that low maternal folate levels is linked to the development of attention-deficit/hyperactivity problems in children at age seven to nine years. Researcher Dr. ...more	29 Oct 2009
Research Identifies Link Between Childhood ADHD And Adult Crime Schoolchildren with attention deficit/hyperactivity disorder are substantially more likely to engage in many types of criminal activity such as burglary, theft and drug dealing as they grow older, a new study by the Yale School of Public Health has found. The research was published in The Journal of Mental Health Policy and Economics. ...more	29 Oct 2009
New CVD Guidelines And Position Papers Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week. ...more	29 Oct 2009
KemPharm, Inc. Announces Initiation Of Phase 1 Trial Of KP106 For ADHD KemPharm, Inc. announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm's proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. ...more	25 Oct 2009
ADHD: Vyvanse Capsules CII Administration Through 2 Routes Demonstrated Similar Pharmacokinetic Profile Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse® (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally. ...more	24 Oct 2009
High Volume Video Gamers Have More Difficulty Staying Attentive Parents have long lectured their children about the mind-numbing effects of playing video games all day. And a new Iowa State University study has found that high volume action video game players -- those who play around 40 hours per week -- actually had more difficulty keeping focused on tasks requiring longer, more proactive attention than those who played video games less than a couple of hours a week. ...more	24 Oct 2009
New Study On Vyvanse(R) (lisdexamfetamine Dimesylate) Capsules CII Shows Administration Of Vyvanse Through Two Different Routes Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse® (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally. ...more	23 Oct 2009
Adult Working Memory May Be Impaired By Amphetamine Use In Adolescence Rats exposed to high doses of amphetamines at an age that corresponds to the later years of human adolescence display significant memory deficits as adults - long after the exposure ends, researchers report. The declines in short-term or "working" memory are most pronounced when the rats are exposed during adolescence, rather than as adults, the researchers found. ...more	22 Oct 2009
Diminished Proactive Attention Exoerienced By Action Video Game Players Video game players are often accused of passively reacting to tasks that are spoon fed to them through graphics and stimuli on the screen. A group of researchers from Iowa State University shows that playing lots of video games has different effects on two types of cognitive activity, proactive and reactive attention. Proactive attention can be thought of as a sort of "gearing up" mechanism. ...more	14 Oct 2009
Liquorice Consumption In Pregnancy May Affect Eating Liquorice In Pregnancy May Affect A Child's IQ And Behavior Expectant mothers who eat excessive quantities of liquorice during pregnancy could adversely affect their child's intelligence and behaviour, a study has shown. A study of eight year old children whose mothers ate large amounts of liquorice when pregnant found they did not perform as well as other youngsters in cognitive tests. They were also more likely to have poor attention spans and show disruptive behaviour such as ADHD (attention deficit hyperactivity disorder). ...more	08 Oct 2009
Addrenex Pharmaceuticals Files SNDA Submission For Clonicel To Treat ADHD Addrenex Pharmaceuticals and Sciele Pharma, Inc., a Shionogi company announced that Addrenex has submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) for Clonicel (modified-release clonidine) to treat attention deficit hyperactivity disorder (ADHD). The submission is based on the successful completion of Phase III clinical trials demonstrating statistical significance when Clonicel was used to treat ADHD in children and adolescents. ...more	04 Oct 2009
First-Ever Drug Effectiveness Study On College Students With ADHD When they think of attention deficit hyperactivity disorder, most people think of squirming kids unable to sit still. ADHD, as it is more generally known, is one of the most common disorders of childhood. But symptoms of ADHD often linger into adulthood. Approximately 2 to 4 percent of college students report significant symptoms of ADHD such as difficulty with attention, impulse control, and restlessness. ...more	25 Sept 2009
Pages of Results: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 [Next] [Last Page]
ADHD News courtesy of Medical News Today	back to top

Medical News

Looking for a Job?

Career Center

Popular Tools

Disclaimer Contact Us Privacy Policy Website Search	We comply with the HONcode standard for health trustworthy information: Verify here. Copyright © 2007 GlobalRPh Inc.